IRadimed Corporation (IRMD) P/E Ratio History
Premium ValuationTrading at 52.4x vs 5Y avg 42.9x · 70th percentile · Premium to historical baseline · Data 2014–2026
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, IRadimed Corporation (IRMD) trades at a price-to-earnings ratio of 52.4x, with a stock price of $91.69 and trailing twelve-month earnings per share of $1.83.
The current P/E is 22% above its 5-year average of 42.9x. Over the past five years, IRMD's P/E has ranged from a low of 27.7x to a high of 79.5x, placing the current valuation at the 70th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, IRMD trades at a 137% premium to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
The PEG ratio of 0.71 (P/E divided by 17% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, IRMD commands a significant premium over the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our IRMD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
IRMD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
IRMD P/E vs Peers
Patient monitoring and wearable diagnostics peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 31.1 | - | -22% | |
| $28B | 13.3 | - | +5% | |
| $20B | 25.3 | 2.25 | +28% | |
| $4B | 31.2 | - | +5% | |
| $2B | 6.9Lowest | 0.66Best | +817%Best | |
| $117B | 36.3 | 2.46 | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
IRMD Historical P/E Data (2014–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $96.26 | $1.83 | 52.6x | -15% |
| FY2025 Q4 | Dec 31 2025 | $97.28 | $1.75 | 55.6x | -10% |
| FY2025 Q3 | - | $71.16 | $1.65 | 43.1x | -30% |
| FY2025 Q2 | Jun 30 2025 | $59.79 | $1.62 | 36.9x | -40% |
| FY2025 Q1 | Mar 31 2025 | $52.48 | $1.55 | 33.9x | -45% |
| FY2024 Q4 | - | $55.00 | $1.50 | 36.7x | -41% |
| FY2024 Q3 | Sep 30 2024 | $50.29 | $1.46 | 34.4x | -44% |
| FY2024 Q2 | Jun 30 2024 | $43.94 | $1.46 | 30.1x | -51% |
| FY2024 Q1 | Mar 31 2024 | $43.99 | $1.41 | 31.2x | -49% |
| FY2023 Q4 | Dec 31 2023 | $47.47 | $1.36 | 34.9x | -43% |
| FY2023 Q3 | Sep 30 2023 | $44.37 | $1.29 | 34.4x | -44% |
| FY2023 Q2 | Jun 30 2023 | $47.74 | $1.16 | 41.2x | -33% |
| FY2023 Q1 | Mar 31 2023 | $39.35 | $1.09 | 36.1x | -41% |
| FY2022 Q4 | Dec 31 2022 | $28.29 | $1.02 | 27.7x | -55% |
| FY2022 Q3 | Sep 30 2022 | $30.06 | $1.04 | 28.9x | -53% |
| FY2022 Q2 | - | $33.94 | $0.97 | 35.0x | -43% |
| FY2022 Q1 | - | $44.84 | $0.83 | 54.0x | -12% |
| FY2021 Q4 | Dec 31 2021 | $46.21 | $0.74 | 62.4x | +1% |
| FY2021 Q3 | - | $33.59 | $0.48 | 70.0x | +13% |
| FY2021 Q2 | Jun 30 2021 | $29.41 | $0.37 | 79.5x | +29% |
| FY2021 Q1 | Mar 31 2021 | $25.77 | $0.08 | 322.1x | +422% |
| FY2020 Q4 | - | $22.80 | $0.11 | 207.3x | +236% |
| FY2020 Q3 | Sep 30 2020 | $21.38 | $0.32 | 66.8x | +8% |
| FY2020 Q2 | - | $23.21 | $0.43 | 54.0x | -12% |
| FY2020 Q1 | - | $21.35 | $0.77 | 27.7x | -55% |
| FY2019 Q4 | - | $23.38 | $0.78 | 30.0x | -51% |
| FY2019 Q3 | Sep 30 2019 | $21.02 | $0.66 | 31.8x | -48% |
| FY2019 Q2 | Jun 30 2019 | $20.45 | $0.66 | 31.0x | -50% |
| FY2019 Q1 | Mar 31 2019 | $28.09 | $0.60 | 46.8x | -24% |
| FY2018 Q4 | Dec 31 2018 | $24.46 | $0.52 | 47.0x | -24% |
| FY2018 Q3 | Sep 30 2018 | $37.15 | $0.40 | 92.9x | +51% |
| FY2018 Q2 | Jun 30 2018 | $20.75 | $0.22 | 94.3x | +53% |
| FY2018 Q1 | Mar 31 2018 | $14.40 | $0.14 | 102.9x | +67% |
| FY2017 Q4 | Dec 31 2017 | $15.15 | $0.05 | 313.7x | +409% |
| FY2017 Q3 | Sep 30 2017 | $9.60 | $0.13 | 74.8x | +21% |
| FY2017 Q2 | Jun 30 2017 | $8.60 | $0.24 | 36.1x | -41% |
| FY2017 Q1 | Mar 31 2017 | $8.90 | $0.40 | 22.3x | -64% |
| FY2016 Q4 | Dec 31 2016 | $11.10 | $0.61 | 18.2x | -70% |
| FY2016 Q3 | Sep 30 2016 | $16.99 | $0.70 | 24.3x | -61% |
| FY2016 Q2 | - | $21.76 | $0.72 | 30.2x | -51% |
| FY2016 Q1 | - | $19.16 | $0.68 | 28.2x | -54% |
| FY2015 Q4 | - | $28.03 | $0.61 | 46.0x | -25% |
| FY2015 Q3 | Sep 30 2015 | $24.36 | $0.44 | 55.4x | -10% |
| FY2015 Q2 | - | $23.27 | $0.31 | 75.1x | +22% |
| FY2015 Q1 | - | $15.23 | $0.26 | 59.1x | -4% |
| FY2014 Q4 | Dec 31 2014 | $12.90 | $0.19 | 68.6x | +11% |
| FY2014 Q3 | - | $7.01 | $0.21 | 32.8x | -47% |
Average P/E for displayed period: 61.7x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IRMD — Frequently Asked Questions
Quick answers to the most common questions about buying IRMD stock.
What is IRMD's P/E ratio?
IRadimed Corporation (IRMD) trailing twelve-month P/E ratio is 52.4x, based on TTM diluted EPS of $1.83. The 5-year average P/E is 42.9x and the historical range spans 27.7x to 79.5x.
Is IRMD stock overvalued or undervalued?
IRMD trades at 52.4x P/E, above its 5-year average of 42.9x. The 70th percentile ranking within the 27.7x–79.5x historical range indicates a premium to historical valuation.
Is IRMD stock expensive?
Yes, IRMD is expensive relative to its own history. The current P/E of 52.4x is above the 5-year average of 42.9x and also above the Healthcare sector median of 22.1x. The stock sits at the 70th percentile of its 5-year valuation range.
What is IRMD's historical P/E range?
Over the past 5 years, IRMD's P/E ratio has ranged from 27.7x to 79.5x, with a median of 36.7x and an average of 42.9x. The current P/E of 52.4x places the stock at the 70th percentile of this range. Full historical data spans 2014–2026.
How does IRMD's P/E compare to the S&P 500?
IRMD trades at 52.4x P/E versus the S&P 500 median of 24.3x. The 116% premium to the market typically reflects higher expected earnings growth or quality.
How does IRMD's valuation compare to Healthcare peers?
IRadimed Corporation P/E of 52.4x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is IRMD's PEG ratio?
IRMD PEG ratio is 0.71, based on a P/E of 52.4x and EPS growth of 16.7%. A PEG below 1.0 indicates the valuation is supported by the earnings growth rate — typically considered attractive.
What is IRMD's earnings yield?
IRMD earnings yield is 1.91%, the inverse of its 52.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.